SREBF1 and metabolic dysfunction-associated steatotic liver disease: Another study enrolling 22 NAFLD patients and 16 control subjects also revealed that liver PPARγ and SREBP-1c mRNA expression was higher in NAFLD patients compared with control subjects [25].